title: Teriflunomide for oral therapy in multiple sclerosis.
abstract: Teriflunomide, the active metabolite of an approved antirheumatic drug, is an emerging oral therapy for multiple sclerosis (MS). Next to the inhibition of pyrimidine biosynthesis and proliferation of activated lymphocytes, it seems to have multiple anti-inflammatory and immunomodulating effects. Phase II and III clinical trials in relapsing MS demonstrated favorable safety and tolerability of the drug, as well as clinical efficacy, with a significant reduction of relapse rate, comparable with those of the available injectable immunomodulatory agents. While multiple other studies with teriflunomide are currently ongoing, its exact place in future treatment algorithms for MS is difficult to predict. It may be a good alternative for patients wishing to have an oral treatment with relatively large data regarding long-term safety.
authors.affiliation: Department of Neurology, University Hospital of Basel, Switzerland.
authors.forename: Athina
authors.initials: A
authors.lastname: Papadopoulou
authors.forename: Ludwig
authors.initials: L
authors.lastname: Kappos
authors.forename: Till
authors.initials: T
authors.lastname: Sprenger
mesh_terms: D000284:Administration, Oral; D003437:Crotonates / Q000008:administration & dosage*; D006801:Humans; D006885:Hydroxybutyrates; D007155:Immunologic Factors / Q000008:administration & dosage*; D009103:Multiple Sclerosis / Q000188:drug therapy*; D009570:Nitriles; D014052:Toluidines / Q000008:administration & dosage*
chemical_list: D003437:Crotonates; D006885:Hydroxybutyrates; D007155:Immunologic Factors; D009570:Nitriles; D014052:Toluidines; C527525:teriflunomide